LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・Roivant Sciences Ltd

Roivant Sciences Ltd

Cerrado

SectorSanidad

29.29 -0.75

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

29.2

Máximo

29.61

Métricas clave
By Trading Economics
Ingresos	-200M -314M
Ventas	428K 2M
Margen de beneficios	-15,692.896
Empleados	750
EBITDA	-132M -290M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+20.55% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	5.5B 21B
Apertura anterior	30.04
Cierre anterior	29.29

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

305 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

11 / 11.18 Soporte y Resistencia

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 may 2026, 22:47 UTC

Acciones populares

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 may 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 may 2026, 22:00 UTC

Principales Movimientos del Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 may 2026, 18:09 UTC

Principales Movimientos del Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 may 2026, 16:02 UTC

Ganancias

Principales Movimientos del Mercado

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 may 2026, 14:55 UTC

Principales Movimientos del Mercado

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 may 2026, 14:43 UTC

Principales Movimientos del Mercado

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 may 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 may 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 may 2026, 21:16 UTC

Charlas de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 20:19 UTC

Acciones populares

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 may 2026, 19:41 UTC

Adquisiciones, fusiones, absorciones

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 may 2026, 19:35 UTC

Charlas de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 may 2026, 18:35 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 may 2026, 17:28 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 may 2026, 16:50 UTC

Adquisiciones, fusiones, absorciones

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 may 2026, 16:24 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 may 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 15:55 UTC

Charlas de Mercado

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 may 2026, 15:20 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 may 2026, 15:20 UTC

Charlas de Mercado

Silver Plunges on Inflation Worries -- Market Talk

15 may 2026, 15:20 UTC

Ganancias

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 may 2026, 14:33 UTC

Charlas de Mercado

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

20.55% repunte

Estimación a 12 Meses

Media 35.31 USD 20.55%

Máximo 41 USD

Mínimo 29.5 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Roivant Sciences Ltd Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

305 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.